Answers are grounded in this paper and cite their sources.
Long COVID, or post-acute sequelae of SARS-CoV-2 (PASC), affects an estimated 10–20% of individuals following SARS-CoV-2 infection. Despite its substantial global burden, the pathophysiological mechanisms remain incompletely understood. This systematic review aimed to synthesize available evidence on viral persistence, immune activation, and histopathological changes across multiple organ systems, drawing from studies of individuals with Long COVID as well as broader post-acute cohorts, autopsy investigations, and case-based reports relevant to Long COVID pathophysiology. Following PRISMA guidelines and holding a PROSPERO registration (CRD420261403869), a systematic literature search was conducted across PubMed, Scopus, EMBASE, and Cochrane CENTRAL. Eligible reports were stratified as (A) symptom-defined Long COVID assessed at or after 12 weeks, (B) post-acute or mixed populations without a consistently confirmed Long COVID definition or timing, (C) autopsy studies, and (D) isolated case/fetal reports. Findings were synthesized narratively by specimen, assay target, and unit of analysis. JBI checklists were used for item-level appraisal, not as certainty-of-evidence ratings. Forty-five reports were included: 16 in stratum A, 23 in stratum B, three autopsy studies, and three isolated case/fetal reports. SARS-CoV-2 genomic RNA, viral proteins, and markers compatible with recent viral activity were reported in selected tissue and blood compartments, but detection varied with population selection, timing, specimen, and assay. No included study established replication competence by recovery of infectious virus. Histopathological abnormalities included inflammatory infiltrates, fibrosis, and vascular injury; however, causal attribution to Long COVID was limited by acute disease severity, biopsy indication, comorbidity, and incomplete comparator data. A single participant total was not reported because of overlapping cohorts, repeated sampling, and outcome-specific denominators. The review supports biological heterogeneity after SARS-CoV-2 infection, including residual viral material, immune dysregulation, vascular injury, and maladaptive tissue repair. Organ-specific prevalence, a hierarchy of tissue tropism, replication-competent reservoirs, and superiority of antiviral or immunomodulatory treatment remain undefined. Standardized Long COVID definitions, representative cohorts, validated assays, appropriate comparators, and longitudinal studies linking biological markers to clinical outcomes are required.
No takes yet. Share an insight, caveat, or question.
Elmahroky et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: